Telesis Bio, Inc.
TBIO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.24 | -0.55 | -1.28 | -2.57 |
| FCF Yield | -17.05% | -6.79% | -0.68% | -0.16% |
| EV / EBITDA | -6.12 | -14.38 | -156.50 | -613.45 |
| Quality | ||||
| ROIC | -72.70% | -67.89% | -32.66% | -70.08% |
| Gross Margin | 61.62% | 56.84% | 38.93% | 55.12% |
| Cash Conversion Ratio | 0.73 | 0.80 | 0.94 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.56% | 60.98% | 31.97% | 66.68% |
| Free Cash Flow Growth | 15.14% | -12.01% | -147.37% | -140.92% |
| Safety | ||||
| Net Debt / EBITDA | -0.81 | 0.21 | 1.82 | 0.32 |
| Interest Coverage | -14.99 | -23.78 | -25.84 | -23.71 |
| Efficiency | ||||
| Inventory Turnover | 2.62 | 5.38 | 2.85 | 4.91 |
| Cash Conversion Cycle | 105.03 | 105.74 | 114.05 | 52.80 |